TrialsgrambetaRCTs are beautiful

monarchE

2020

Adjuvant Abemaciclib in High-Risk HR+/HER2– Early Breast Cancer

In 5,637 patients with HR+/HER2– node-positive high-risk early breast cancer, two years of abemaciclib added to endocrine therapy reduced invasive disease-free survival events compared with endocrine therapy alone.

Result

Efficacy: Invasive disease-free survivalHR 0.68

Below 1 favours two years of abemaciclib added to endocrine therapy, above 1 favours endocrine therapy alone.

Event rates
Absolute difference
7.6 points

The absolute difference is derived from the event rates.

Also reported: Distant relapse-free survival HR 0.675.

Original publication
Subtopic
HR+/HER2– adjuvant
Design
Open-label RCT
Relevance
Important: one of several pillars.
Source
Johnston SRD, et al. J Clin Oncol. 2020;38(34):3987-3998; Rastogi P, et al. J Clin Oncol. 2024;42(9):987-993.doi 10.1200/JCO.20.02514

Discussion & critique

First CDK4/6 inhibitor with adjuvant benefit. OS data still maturing; benefit absolute but small in lower-risk subsets.